Malignancy Spectrum最新文献

{"title":"The result of maintenance therapy with rituximab in extra nodal lymphoma","authors":"Mozaffar Aznab,&nbsp;Fatemeh Heydarpur,&nbsp;Amirmasoud Rahimi,&nbsp;Sayed Javad Hossini,&nbsp;Kiumrs Eslampia","doi":"10.1002/msp2.70011","DOIUrl":"https://doi.org/10.1002/msp2.70011","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Maintenance treatment with rituximab has been used in some nodal lymphomas, such as follicular and diffuse large cell lymphoma. The aim of this study was to evaluate the survival of extra nodal lymphoma patients under maintenance treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>From July 2008 to December 2017, after induction treatment in patients with extra nodal lymphoma, if the patients consented and the drug was available, they were treated with rituximab every 3 months for 2 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 112 patients with extra nodal lymphoma met the inclusion criteria. Among them, 89 patients had high-grade lymphomas and 23 patients were in the group of low-grade lymphomas. The group of patients with high-grade lymphoma who received the rituximab-containing regimen as a maintenance treatment had lower rates of recurrence and death compared to the group that received rituximab only in the induction phase. In patients with low-grade lymphoma, the recurrence rate and mortality were also lower in the group receiving maintenance treatment compared to other groups, but the difference was not statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The use of rituximab in patients with extra nodal lymphoma as maintenance can increase the survival of the patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"95-102"},"PeriodicalIF":0.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A gene panel to predict response to adjuvant chemotherapy and risk of recurrence in colorectal cancer","authors":"Steffie Urmila Avanthi,&nbsp;Ravikanth Vishnubhotla,&nbsp;Mitnala Sasikala,&nbsp;Guduru Venkat Rao,&nbsp;Rebala Pradeep,&nbsp;Sanjeev Marigowda Patil,&nbsp;Anuradha Sekaran,&nbsp;Jain Aviral,&nbsp;Sonali Mondkar,&nbsp;Nageshwar Reddy Duvvur","doi":"10.1002/msp2.70009","DOIUrl":"https://doi.org/10.1002/msp2.70009","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chemotherapy is the mainstay to treat metastatic colorectal cancer (CRC). However, a sizeable proportion of patients do not respond to treatment, which leads to the recurrence of disease. This study was carried out to identify reliable gene expression-based marker(s) to predict the response to chemotherapy and the risk of recurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study involved the collection of tumor tissues (<i>n</i> = 100) and normal tissues (<i>n</i> = 10) from CRC patients who primarily underwent surgical treatment. Global gene expression profiles were generated on microarray (Affymetrix; <i>n</i> = 5) and the next-generation sequencing (NGS) (Illumina; <i>n</i> = 20) platforms. Patients were classified as responders (<i>n</i> = 13; complete response with no relapse) or non-responders (<i>n</i> = 12; recurrence of disease leading to death). Common dysregulated genes identified from both platforms were replicated in an independent set (<i>n</i> = 75; quantitative real-time polymerase chain reaction (qRT-PCR)). The area under the curve (AUC) was generated, and a combinatorial analysis was performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 193 and 1351 genes were dysregulated in microarray and NGS datasets, respectively. Of the top common genes (<i>PTGIS</i>, <i>LYVE1</i>, <i>C3</i>, <i>C7</i>, <i>CXCL12</i>, <i>CEACAM6</i>, <i>MUC13</i>, and <i>ST14)</i> that were selected for replication, upregulation of five genes (<i>PTGIS</i>, <i>C3</i>, <i>C7</i>, <i>LYVE1</i>, and <i>CXCL12</i>) were associated with the non-responder group in validation set. Combinatorial analysis and comparison of AUC identified a significant increase (<i>p</i> = 0.03) in AUC by 15.2% (95% confidence interval (CI): 0.01−0.29) for two genes (<i>PTGIS</i> and <i>LYVE1</i>). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 88.9%, 100%, 100%, and 95.6%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Assessing upregulation of the <i>PTGIS</i> and <i>LYVE1</i> genes enables identification of individuals who may not respond to adjuvant chemotherapy and the risk of recurrence. The addition of drugs targeting these genes may improve response and benefit the patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"84-94"},"PeriodicalIF":0.0,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of miR-4284 in cancer progression and therapeutic response: Regulatory mechanisms and clinical implications","authors":"Chenhao Liang,&nbsp;Yaojie Feng,&nbsp;Yuhua Zhang,&nbsp;Zehua Wang,&nbsp;Xinming Su,&nbsp;Shiwei Duan","doi":"10.1002/msp2.70008","DOIUrl":"https://doi.org/10.1002/msp2.70008","url":null,"abstract":"<p>As a pivotal microRNA (miRNA), miR-4284 exhibits noteworthy aberrant expression levels across various cancers and diseases, exerting a crucial role in modulating cancer progression and prognosis. This article endeavors to comprehensively elucidate the regulatory mechanisms of miR-4284 in cancer, delving deeply into its impact on tumor cell proliferation, invasion, and metastasis by intervening in key signaling pathways such as p65, mitogen-activated protein kinase (MAPK), and transforming growth factor-β (TGF-β). Moreover, this article examines the potential associations of miR-4284 with diverse current therapeutic strategies, such as cancer prediction models, synergistic effects of chemotherapeutic agents, mechanisms of ultrasound-targeted microbubble destruction technology, and enhancement of radiotherapy. However, despite the significant strides made in miR-4284 research, certain limitations persist. Looking ahead, we anticipate that larger-scale and more in-depth studies will further unveil the functional mechanisms of miR-4284 and elucidate its role in therapeutic drug efficacy, thus furnishing robust theoretical underpinnings for the clinical application of miR-4284.</p>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"59-73"},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart failure during adjuvant therapy for breast cancer: A case report","authors":"Huan Zhang,&nbsp;Zhao Ma,&nbsp;Shuwen Yang,&nbsp;Linqi Liu,&nbsp;Shu Zhou,&nbsp;Lanxin Feng,&nbsp;Ran Ran,&nbsp;Wenyang Liu,&nbsp;Chenchen Tu,&nbsp;Xiantao Song,&nbsp;Hongjia Zhang","doi":"10.1002/msp2.70010","DOIUrl":"https://doi.org/10.1002/msp2.70010","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer is one of the most common malignant tumors among women worldwide. Chemotherapeutic and targeted agents, as important adjuvant therapy for breast cancer, can also cause cardiotoxicity, leading to cardiac dysfunction. It is essential to recognize cardiotoxicity early, cease drug exposure when appropriate, and initiate heart failure therapy. Currently, echocardiography is routinely used to monitor cardiac function during treatment. However, normal left ventricular ejection fraction (LVEF) measured by echocardiography cannot exclude cardiotoxicity. Therefore, more sensitive cardiac monitoring tools are needed. Optical pumped magnetometer-magnetocardiography (OPM-MCG) has been proved to be a noninvasive and effective means to detect and monitor myocardial injury.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case description</h3>\u0000 \u0000 <p>In this case, we presented a patient diagnosed with early breast cancer with human epidermal growth factor receptor 2 (HER2) overexpression, following adjuvant therapy with paclitaxel liposomes, trastuzumab, and pertuzumab. Heart failure with reduced ejection fraction (HFrEF) occurred after five cycles of anti-HER2 therapy, which improved with chronic heart failure (CHF) treatment. The MCG scan of this patient was significantly abnormal when she developed symptomatic HFrEF, which improved gradually during CHF treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The patient's heart failure was most likely caused by HER2-targeted agents, which was reversible and could be improved with the administration of angiotensin receptor neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitor (SGLT2i). In the future, OPM-MCG may act as a safe, accurate, and efficient evaluation tool for cardiotoxicity monitoring to detect early myocardial injury in cancer patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"110-115"},"PeriodicalIF":0.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT) for a young adult male with primary tracheal carcinoma: A case report demonstrating 5-year long-term survival","authors":"Xueling Chen,&nbsp;Xuejian Ning,&nbsp;Tao Si","doi":"10.1002/msp2.70006","DOIUrl":"https://doi.org/10.1002/msp2.70006","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The incidence of primary tracheal neoplasm is extremely rare. Squamous cell carcinoma (SCC) is the most prevalent histological type of tracheal malignancy. Postoperative adjuvant radiotherapy can be considered as a curative management option. However, there are limited data available on the use of radiotherapy or concurrent chemoradiotherapy for tracheal cancer, particularly intensity-modulated radiotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patient and methods</h3>\u0000 \u0000 <p>Herein, we present a case report of a young adult male diagnosed with primary SCC of the trachea who underwent postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT). The treatment included 50.4 Gy radiation in 28 fractions and two cycles of chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The patient experienced grade Ⅰ dermatitis and grade Ⅱ granulocytosis. Follow-up showed no evidence of recurrence or significant adverse effects. The patient achieved 5-year long-term survival with good quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Postoperative concurrent chemoradiotherapy using IMRT is effective for primary tracheal carcinoma, offering long-term survival and quality of life benefits.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"103-109"},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of pre-surgery nutrition intervention on weight loss, nutrition status, and quality of life in colorectal cancer patients with elective surgery","authors":"Wen Lynn Teong,&nbsp;Wei Yee Wong,&nbsp;Su Lin Lim,&nbsp;Choon Hui Low,&nbsp;Cassandra Lim Duan Qi,&nbsp;Ruochen Du","doi":"10.1002/msp2.70007","DOIUrl":"https://doi.org/10.1002/msp2.70007","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Weight loss in colorectal cancer (CRC) surgical patients is widespread and often associated with increased morbidity and mortality. This study aimed to determine whether pre-surgery nutrition intervention in CRC patients can reduce post-surgery weight loss and improve nutritional status and quality of life (QoL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Sixty CRC patients undergoing elective surgery from November 2018 to February 2021 were recruited. They were compared to a control group of 60 CRC patients extracted retrospectively from 2014. The intervention group received pre-surgery nutrition counselling and was followed up at 1, 2, and 3 months after surgery, where their weights were taken and nutritional status was assessed using Subjective Global Assessment (SGA). Health-related QoL was assessed using the 3-level Euro-Quality of Life 5 Domain (EQ-5D-3L) questionnaire before surgery and at 3 months after surgery. The control group did not receive pre-surgery nutrition counselling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At 3 months after surgery, the intervention group lost significantly less weight compared to the control group (<i>p</i> &lt; 0.001). Similar significant results were observed at 1 and 2 months after surgery (<i>p</i> &lt; 0.001). Fifty-two patients (91%) in the control group lost weight compared to 31 patients (53%) in the intervention group at 3 months after surgery (<i>p</i> &lt; 0.001). Within the intervention group, the post-surgery Quality of Life Visual Analogue Scale improved significantly from baseline (80% versus 75%, <i>p</i> = 0.043). The SGA score at 3 months after surgery was similar to that of baseline (<i>p</i> = 0.109).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pre-surgery nutrition intervention in patients with CRC and elective surgery has resulted in a significant reduction in post-surgery weight loss, improvement in QoL, and maintenance of nutritional status.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"74-83"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of pediatric systemic juvenile xanthogranuloma","authors":"Feifei Liu,&nbsp;Man Hu,&nbsp;Rui Zhang,&nbsp;Zhigang Li,&nbsp;Hongyun Lian","doi":"10.1002/msp2.70003","DOIUrl":"https://doi.org/10.1002/msp2.70003","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Juvenile xanthogranuloma (JXG) is a rare disorder that belongs to the broad group of non-Langerhans cell histiocytosis. It is characterized by one or more nodules with predilection sites on the head, neck, and trunk, and lesions that may be several millimeters in diameter. These are reddish or yellowish benign papules or nodules that usually resolve spontaneously. The involvement of organs other than the skin is termed systemic juvenile xanthogranuloma (SJXG). The eye is the most frequent extracutaneous location of the JXG.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>We report a case of SJXG in a male child, with onset in the second month of life. He presented with several nodules, approximately 5 mm in diameter and tan-orange in color, located on the head, face, and trunk. The nodules enlarged to 10 mm in diameter, and new lesions were found in the right eye, which resulted in spontaneous hyphema and secondary glaucoma without treatment. The pathological findings suggested that the nodule was of histiocytic origin, and immunohistochemical analysis resulted in the diagnosis of JXG. Chemotherapy based on the Langerhans cell histiocytosis (LCH) regimen resulted in a good prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>SJXG has low morbidity, but is unpredictable, and rare and self-limited. Treatment is required for patients with extracutaneous involvement, who may have increased morbidity. The LCH-Ⅲ protocol of the International Histiocyte Society is the most commonly used and effective chemotherapy regimen.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 1","pages":"53-58"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCL2, IRS1, AKT3, PTEN, and HIF1A expression levels in non-small cell lung cancer patients","authors":"Mahdi Mohammadi,&nbsp;Kiana Taheri,&nbsp;Shamim Fooladgar,&nbsp;Saghar Omidvar Masoumi,&nbsp;Elham Tafsiri","doi":"10.1002/msp2.70002","DOIUrl":"https://doi.org/10.1002/msp2.70002","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lung cancer is the leading cause of cancer-related deaths worldwide. MicroRNAs (miRNAs) are small noncoding molecules that play critical roles in cell proliferation, apoptosis, invasion, and metastasis, and they can target multiple genes at the mRNA level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>Some online tools like TargetScan, miRDIP, miRmap, and miRanda were used to evaluate the validated target genes. Before choosing target genes, we took advantage of some bioinformatics tools including STRING, GeneMANIA, and TRED to predict the target genes. Finally, the expression levels of the target genes were measured in non-small cell lung cancer (NSCLC) tumor and their adjacent normal tissues via SYBR Green-based quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>According to bioinformatics tools, <i>BCL2</i> and <i>AKT3</i> were selected as target genes for miR-15/16, and BCL2 was shown to demonstrate a robust negative correlation with miR-15a in our previous analysis of NSCLC tumor samples. Furthermore, we found a significant correlation between <i>BCL2</i> expression level and stage Ⅲ (<i>p</i> = 0.04). <i>PTEN</i> was assumed as a validated target gene of miR-21 that presented a significant decrease in tumor tissues compared to adjacent normal tissues. <i>IRS1</i> was assigned as a target gene of miR-126/miR-128, and finally, <i>HIF1A</i> was selected as the target gene of miR-210. There was a significant negative association between <i>IRS1</i> expression level and miR-126/miR-128, but a positive correlation was demonstrated between miR-210 and <i>HIF1A</i> at mRNA level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Restoration of miR-15/16, miR-126, and miR-128 in NSCLC might be therapeutic candidates to control cell proliferation and apoptosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 1","pages":"37-45"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The state of cervical cancer screening in Vanuatu: A retrospective analysis (2015–2020)","authors":"Emma R. Allanson,&nbsp;Vera Velanova,&nbsp;Boniface Damutalau,&nbsp;Harriet Obed,&nbsp;Geetha Warrier,&nbsp;Ian H. Frazer,&nbsp;Margaret McAdam","doi":"10.1002/msp2.70004","DOIUrl":"https://doi.org/10.1002/msp2.70004","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Vanuatu is a lower- and middle-income country in the Pacific with a cervical cancer incidence of 100 per 100,000 women. An opportunistic screening program has existed since 2008, with continuous data collection related to this since 2015.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analysed all cervical cancer screening data for Vanuatu over 6 years, and conducted a descriptive analysis of number of women screened, the results of screening, the treatment rates of human papillomavirus (HPV) positivity or cytological abnormalities detected through screening, and the incidence of cervical cancer. The challenges encountered during the implementation of the screening program are also described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data were available from 01/01/2015 to 31/12/2020. Based on census data, 70,081 women were eligible for screening, and 15,696 (22.4%) women underwent screening at least once. Screening coverage included 13.2% of individuals under 30 years, 33.2% of individuals in the 30−50 age group, and 15.8% of people over 50 years. A total of 8910 HPV tests were conducted, of which 876 (9.8%) were positive. Among the HPV-positive cases, 316 received large loop excision of the transformation zone (LLETZ) treatment, 156 (49.4%) of which were high grade and 2 (0.6%) of which were cancer. A total of 13,396 Pap smear tests were conducted, with 315 (2.4%) showing high-grade results and 226 (1.7%) indicating possible high-grade results. Overall, 119 cancers were diagnosed from 15,696 women screened (0.8%), including 6/3297 (0.2%) of &lt; 30 years, 75/10,089 (0.7%) of 30−50 years, 38/2310 (1.6%) of &gt; 50 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>One in five eligible Ni-Vanuatu women have undergone cervical cancer screening since 2015, with 7.6 per 1000 women having malignant results and 40.4 per 1000 women having high-grade or possible high-grade results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 1","pages":"46-52"},"PeriodicalIF":0.0,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of graded motor imagery on fear of movement, pain, and rehabilitation in patients with kinesiophobia after video-assisted thoracoscopic surgery for lung cancer: A randomized controlled trial","authors":"Xinyuan Zhang,&nbsp;Xiaohong Zhang,&nbsp;Xingu Chen,&nbsp;Shuping Liang,&nbsp;Yan Yu,&nbsp;Hui Li,&nbsp;Qunqing Chen,&nbsp;Li Li","doi":"10.1002/msp2.70001","DOIUrl":"https://doi.org/10.1002/msp2.70001","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to evaluate the effects of graded motor imagery (GMI) on fear of movement, pain, and rehabilitation in patients with kinesiophobia after video-assisted thoracoscopic surgery (VATS) for lung cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty-eight participants with kinesiophobia after VATS were randomly assigned into two groups: one receiving usual care (the control group) and the other receiving usual care plus GMI (the GMI group). The GMI was delivered in three stages: left/right limb identification, motor imagery, and mirror therapy delivered by two researchers every afternoon starting on the first postoperative day, once a day for about 40 min, at least twice. Level of fear of movement, pain-related patient-reported outcomes (PROs), rehabilitation exercise participation, and peak expiratory flow (PEF) were compared between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-seven eligible participants were included in the GMI group and 29 in the control group. Compared to the reports on the first postoperative day, the participants who received GMI reported at discharge significant reductions in kinesiophobia, intensity of worst pain and least pain, and interference of pain with activities and emotions, and increases in rehabilitation exercise participation and PEF than those in the control group (<i>p</i> &lt; 0.05). An unexpected finding was a reduced surgery-to-discharge interval in the patients who received GMI (almost a day earlier than those in the control group).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GMI can reduce fear of movement, improve pain-related PROs, and increase rehabilitation exercise participation and PEF for lung cancer patients with kinesiophobia after VATS.</p>\u0000 \u0000 <p>The study was registered at the Chinese Clinical Trial Registry (ChiCTR2300072612).</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}